Skyai, Inc. annual report, FY2022

Business context and reporting period

Filing identity: The request identifies Skyai, Inc., but the supplied Form 10-K is for Sharps Technology, Inc. (Nasdaq: STSS; warrants: STSSW). Confirm the intended issuer before relying on this summary. The filing covers the fiscal year ended December 31, 2022, with 2021 comparative results.

Sharps is a pre-revenue medical-device company developing and commercializing safety syringes. Its Securegard and Provensa products combine needle-safety and reuse-prevention features with claimed ultra-low dead space. In July 2022, it acquired Safegard’s Hungarian manufacturing facility and related assets. It also entered into a four-year collaboration with Nephron covering manufacturing support, prefillable syringe systems and pharma services; Nephron was appointed exclusive U.S. distributor for covered products.

Financial performance and liquidity

Metric20222021
Revenue$0$0
Research and development expense$2.28 million$1.69 million
General and administrative expense$6.46 million$2.81 million
Operating loss$8.74 million$4.50 million
Net loss$4.64 million$4.66 million
Basic and diluted loss per share$0.57$0.96
Operating cash used$6.43 million$3.15 million
Investing cash used$3.12 million$2.34 million

There were no sales, so revenue margins are not meaningful. Net loss was nearly flat year over year despite higher operating expenses, chiefly because of a $5.39 million fair-value gain on contingent stock and warrant liabilities. The company reported $1.32 million of net interest expense, including substantial accretion on its 2021 bridge financing.

Cash and cash equivalents at year-end are reported as $4.17 million in the balance sheet and cash-flow statement; the MD&A separately states $4.11 million. Working capital was $2.42 million, versus a $1.16 million deficit in 2021. Total liabilities were $2.20 million, including $1.15 million of warrant liabilities; the $2.0 million bridge note was repaid from IPO proceeds. The filing reports $7.00 million in net fixed assets and $9.64 million in stockholders’ equity.

Operating cash use increased as staffing, public-company costs and development activity grew. Investing outflows included $2.37 million for the Safegard acquisition. The April 2022 IPO generated approximately $14.2 million net; about $10 million had been used by year-end. A February 2023 offering subsequently raised approximately $3.2 million net.

Material changes versus 2021

  • G&A increased 130% to $6.46 million, driven by higher payroll and consulting, marketing, insurance, professional fees and public-company expenses.
  • R&D rose 35% to $2.28 million, reflecting facility staffing and costs after the Safegard acquisition, partially offset by lower pre-acquisition facility operating payments.
  • Sharps acquired and began operating its 41,000-square-foot Hungary facility in July 2022; fixed assets increased to $7.00 million net.
  • The company completed its IPO, repaid the $2.0 million bridge note and moved from a working-capital deficit to positive working capital.
  • Net loss improved slightly, but this did not reflect commercial revenue: the company remained pre-revenue, and the year’s results included a sizable noncash derivative fair-value gain.

Outlook, risks and unusual items

  • Management intends to build inventory, increase production capacity and commercialize Securegard first. Provensa commercialization has been delayed by final-assembly optimization. The filing says no orders had been received to date.
  • Nephron collaboration and distribution arrangements are potential routes to market, not evidence of realized sales. The filing gives differing expected prefillable-product supply dates—mid-2023 in one discussion and the fourth quarter of 2023 elsewhere—and also contains a reference to orders in the second quarter of 2022. Treat these timelines as uncertain.
  • Key risks include continued losses and cash burn, need for additional capital, manufacturing scale-up and product delays, lack of customer orders, competition, regulatory requirements, and product-liability exposure. Product-liability coverage was reported at $5 million.
  • Outstanding warrants are liability-classified and remeasured at fair value, which can materially affect reported earnings. At December 31, 2022, 9.05 million warrants were outstanding; 10.41 million options and warrants were excluded from diluted EPS as antidilutive.
  • A 2% royalty on net sales related to certain intellectual property remains in place. The company also disclosed a dispute with co-chairman Alan Blackman regarding termination of his employment agreement and his allegations of “good reason” and retaliation; the company said it considered the allegations without merit. No material litigation was reported as pending in the legal-proceedings section.
  • One Series A preferred share held by Mr. Blackman carries 29.5% of director-election voting power and specified sale-related rights. Further equity issuance may dilute shareholders. The company reported effective disclosure controls, but its internal-control report was omitted under the transition applicable to newly public companies; the auditor did not opine on internal-control effectiveness.
  • The independent auditor issued an unqualified opinion on the financial statements. No cash dividends are planned. The filing reports no material off-balance-sheet arrangements.

Important facts for investors to verify

  1. Confirm that Sharps Technology, Inc.—not Skyai, Inc.—is the intended issuer and verify the filing period.
  2. Reconcile the year-end cash discrepancy ($4.17 million in the financial statements versus $4.11 million in MD&A) and review subsequent cash use and financing needs.
  3. Check whether Nephron-related supply milestones were achieved, whether commercial orders were obtained, and whether the disclosed timing estimates changed.
  4. Assess production readiness, inventory quality and the remaining Provensa assembly work, alongside regulatory clearances in intended markets.
  5. Review warrant terms and dilution potential, including the February 2023 offering, and evaluate the effect of liability remeasurement on earnings.
  6. Monitor the Blackman employment dispute, related-party obligations, and the ongoing 2% royalty on applicable net sales.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.